Emergent Biosolutions (NYSE:EBS) Reaches New 52-Week High – Time to Buy?

06 Jan 2026, 13:20 by Jessica Moore · The Cerbat Gem

Shares of Emergent Biosolutions Inc. (NYSE:EBS – Get Free Report) reached a new 52-week high on Tuesday . The stock traded as high as $13.58 and last traded at $13.4140, with a volume of 258917 shares traded. The stock had previously closed at $12.85.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Zacks Research upgraded Emergent Biosolutions to a “hold” rating in a research note on Friday, October 24th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Emergent Biosolutions in a research report on Tuesday, December 16th. Wall Street Zen upgraded shares of Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 30th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Emergent Biosolutions in a research note on Monday, December 29th. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $15.00.

Get Our Latest Research Report on EBS

Emergent Biosolutions Trading Up 2.6%

The company has a market cap of $692.48 million, a P/E ratio of 10.13 and a beta of 2.30. The business’s 50-day moving average price is $11.34 and its 200 day moving average price is $9.19. The company has a debt-to-equity ratio of 1.14, a quick ratio of 3.15 and a current ratio of 5.76.

Emergent Biosolutions (NYSE:EBS – Get Free Report) last posted its quarterly earnings results on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) EPS for the quarter. Emergent Biosolutions had a return on equity of 20.85% and a net margin of 9.62%.The business had revenue of $222.50 million for the quarter. As a group, analysts expect that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current year.

Insider Buying and Selling

In other Emergent Biosolutions news, Director Ronald Richard sold 21,984 shares of Emergent Biosolutions stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $11.97, for a total value of $263,148.48. Following the completion of the sale, the director owned 98,417 shares in the company, valued at $1,178,051.49. The trade was a 18.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Emergent Biosolutions

Several large investors have recently bought and sold shares of the business. EP Wealth Advisors LLC boosted its stake in shares of Emergent Biosolutions by 33.1% in the 1st quarter. EP Wealth Advisors LLC now owns 15,249 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 3,790 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in shares of Emergent Biosolutions by 6.0% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 196,384 shares of the biopharmaceutical company’s stock worth $954,000 after acquiring an additional 11,067 shares in the last quarter. Millennium Management LLC boosted its position in shares of Emergent Biosolutions by 68.9% during the 1st quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock valued at $12,162,000 after purchasing an additional 1,020,582 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Emergent Biosolutions by 12.5% during the first quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock worth $5,301,000 after purchasing an additional 121,583 shares during the period. Finally, Acadian Asset Management LLC increased its holdings in Emergent Biosolutions by 313.5% in the first quarter. Acadian Asset Management LLC now owns 833,316 shares of the biopharmaceutical company’s stock worth $4,048,000 after purchasing an additional 631,794 shares in the last quarter. 78.40% of the stock is owned by institutional investors and hedge funds.

About Emergent Biosolutions

(Get Free Report)

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.